Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3272 - The efficacy of everolimus relies on a modulation of adaptative anti tumor T cell immunity


09 Oct 2016


Poster display


Olivier Adotévi


Annals of Oncology (2016) 27 (6): 359-378. 10.1093/annonc/mdw378


O. Adotévi1, L. Mansi1, L. Beziaud1, P. Ravel2, E. Lauret Marie-Joseph1, C. Laheurte1, L. Rangan1, T. Maurina1, G. Mouillet1, T. Nguyen Tan Hon1, E. Curtit1, X. Pivot1, Y. Godet1, C. Borg1, A. Thiery-Vuillemin1

Author affiliations

  • 1 Medical Oncology, CHU Besançon, Hôpital Jean Minjoz, 25030 - Besançon/FR
  • 2 Biostatistic, ICM Regional Cancer Institute of Montpellier, Montpellier/FR


Abstract 3272


The rapalogs everolimus that inhibit mTOR signaling are used as anti-proliferative drugs in metastatic renal cell carcinoma (mRCC). The influence of immune modulation mediated by everolimus on its antitumor efficacy is poorly investigated.


We performed a prospective immunomonitoring study in 23 mRCC patients treated with everolimus.


Study showed that everolimus promoted high expansion of FoxP3+Helios+Ki67+ regulatory CD4 T cells (Tregs). Everolimus exposure strongly enhanced the suppressive functions of patients' Tregs. Paradoxically, a concurrent activation of tumor-specific Th1 immunity also occurred during everolimus treatment. Interestingly, an early change of the Tregs/antitumor Th1 balance can differentially shapes the treatment efficacy. Thus, patients presenting a shift towards Tregs decrease and high expansion of antitumor Th1 response had a better survival (PFS: 13.2 months vs 4.1 months P = 0.02). At the time of disease progression upon everolimus treatment, the majority of mRCC patients totally lost the anti-tumor Th1 response in favor to a marked increase of circulating Tregs.


Altogether, our results describe for the first time a dual impact of host adaptive antitumor T cell immunity on the clinical effectiveness of everolimus. So there is a strong rational to combine everolimus with Tregs or immune checkpoint blockade to shift host immune responses toward protective antitumor immunity.

Clinical trial identification

Legal entity responsible for the study

University Hospital of Besançon France




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings